Relmada (RLMD) - Market Cap to Earnings
Relmada Therapeutics (RLMD) relies on the recognition of psychiatrists and trust in its depression therapy developments. The business creates CNS agents, where current testing costs will be replaced by high profits following patenting. This price chart with the -7.70 metric is available below. However, sanctions and military conflicts complicate the international search for volunteers, slowing the certification of new drugs.
Comprehensive metric breakdowns and analytics for Relmada (RLMD)
- share price and expert price forecast:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Relmada Therapeutics|RLMD - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Relmada Corp|RLMD - Company Aggregate Debts|Debts to Book Capitalization Relmada Therapeutics, Inc.|RLMD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Relmada Therapeutics|Intermediate Liquidity Ratio relmada.com
- earnings and market ratios statistics:
RLMD - Net Profit|Expected Net Income Relmada Therapeutics|RLMD - P/E Multiple|Projected Price to Earnings Ratio Relmada Therapeutics Inc|RLMD - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Relmada Therapeutics, Inc.|RLMD - Operating profit EBITDA|Net earnings per share (EPS TTM) Relmada Therapeutics|RLMD - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months relmada.com|RLMD - Earnings growth in current year|Expected net earnings per share growth next year Relmada Therapeutics
Summary company analysis:RLMD, relmada.com
When constructing a long-term portfolio, asset screening begins by assessing the investment payback period through the ratio of market value to net profit. For Relmada Therapeutics (RLMD), which utilizes production outsourcing to minimize capital expenditures, this metric reflects the efficiency of its scientific model, allowing for detailed tracking of business value dynamics via the company's fundamental P/E on the GURU.Markets platform.
Competing companies
BIIB: Company Value to Net Income|P/E Multiple NBIX|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACADIA Corp - Price to Earnings Ratio|XENE - Price to Earnings Ratio|vikingtherapeutics.com (VKTX) - Price to Earnings Ratio|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|DNLI (Denali Therapeutics Inc) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Corp)|P/E Multiple BHVN|P/E Multiple amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|AVXL: Price to Earnings Ratio|CeriBell EEG - Market Price to Net Income Ratio|PRTA: P/E Multiple|Alector - Company Value to Net Income|ANNX (Annexon) - P/E Multiple|Market Cap to Earnings Omeros Corp. OMER|Price to Earnings Ratio Neurogene Corp (NGNE)|ACIU (AC Immune Inc) - Company Value to Net Income|P/E Multiple VYGR (Voyager Therapeutics)|P/E Multiple neumoratx.com NMRA|SCLX - Price to Earnings Ratio|Market Cap to Net Income TVGN|ACOG: P/E Multiple|Market Cap to Earnings Cognition Therapeutics Inc. (CGTX)|Price to Earnings Ratio IKT|P/E Multiple cassavasciences.com|Price to Earnings Ratio ASRT (Assertio Holdings, Inc.)|Market Price to Net Income Ratio COYA|P/E Multiple VTGN (Vistagen)|Business Payback Period Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals - P/E Multiple|cervomed.com (CRVO) - Price to Earnings Ratio|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|CLNN - Business Payback Period|Price to Earnings Ratio PepGen Inc|JUNS: Company Value to Net Income|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|Price to Earnings Ratio GRCE (gracetx.com)|Price to Earnings Ratio Firefly Neuroscience AIFF|KLTO - Price to Earnings Ratio|NeuroSense Therapeutics, Ltd. - P/E Multiple|RVPH (Reviva Pharmaceuticals, Inc.) - Price to Earnings Multiple|metaviatx.com (MTVA) - Price to Earnings Ratio|Price to Earnings Multiple NRXS|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Market Cap to Earnings Passage Bio Corp PASG|Price to Earnings Ratio NEUP (Neuphoria Therapeutics Inc.)|P/E Multiple Minerva (NERV)|Price to Earnings Ratio Athira Pharma, Inc. ATHA|Company Value to Net Income ADXN|ALZN - Price to Earnings Ratio|Market Cap to Earnings Cyclerion Therapeutics|protagenic.com (PTIX) - Price to Earnings Ratio|Pasithea Therapeutics Corp. - Company Value to Net Income|CRGT (Cortigent Inc) - P/E Multiple|Market Cap to Earnings avenuetx.com ATXI|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|Price to Earnings Ratio CARA (Cara Therapeutics Inc.)|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM - Price to Earnings Ratio|Intra-Cellular - P/E Multiple|LBPH - P/E Multiple|MRNS: P/E Multiple|Price to Earnings Multiple NKGN|NRBO (NeuroBo) - P/E Multiple|P/E Multiple Sage Therapeutics Inc|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Company Value to Net Income|Vigil Neuroscience, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio WENA (anewmeds.com)|Cerevel - P/E Multiple
